Zevra Therapeutics, Inc. 8-K Filing
Ticker: ZVRA · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1434647
| Field | Detail |
|---|---|
| Company | Zevra Therapeutics, Inc. (ZVRA) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Zevra Therapeutics, Inc. (ticker: ZVRA) to the SEC on Dec 2, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ich registered Common Stock, par value $0.0001 per share ZVRA The Nasdaq Stock Market).
How long is this filing?
Zevra Therapeutics, Inc.'s 8-K filing is 3 pages with approximately 859 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 859 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2025-12-02 07:34:13
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share ZVRA The Nasdaq Stock Market
Filing Documents
- zvra-20251126.htm (8-K) — 33KB
- zvra-20251202xex991.htm (EX-99.1) — 10KB
- zevralogoa.jpg (GRAPHIC) — 6KB
- 0001434647-25-000015.txt ( ) — 169KB
- zvra-20251126.xsd (EX-101.SCH) — 2KB
- zvra-20251126_lab.xml (EX-101.LAB) — 21KB
- zvra-20251126_pre.xml (EX-101.PRE) — 12KB
- zvra-20251126_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 2, 2025, the Company issued a press release announcing the matters disclosed above in Item 5.02. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Tenth Amended and Restated Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.1 filed with the Company's Quarterly Report on Form 10-Q filed on May 13, 2025 (File No. 001-36913)) 99.1 Press Release dated December 2 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Zevra Therapeutics, Inc. Date: December 2, 2025 By: /s/ Timothy J. Sangiovanni Timothy J. Sangiovanni, CPA Senior Vice President, Finance and Corporate Controller